The National Health Insurance Service’s Drug Reimbursement Evaluation Committee conducted its first reevaluation to assess the reimbursement adequacy on the anti-inflammatory streptokinase/streptodornase combo and decided that the combination is inadequate for insurance benefit.

The drug has been used to ▲relieve acute inflammatory edema exacerbation due to ankle surgery or trauma, and ▲ to address the expectoration of sputum difficulties that accompany respiratory disorders. However, as the drug is not listed for reimbursement in any of the A8 reference countries (the US, the UK, France, Italy, Japan, Germany, Switzerland, and Canada), the combination was highly likely to receive negative results d